XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.860
- +0.030+1.64%
Close Feb 14 16:00 ET
- 1.802
- -0.058-3.13%
Post 17:36 ET
92.64MMarket Cap-0.60P/E (TTM)
1.880High1.810Low119.81KVolume1.840Open1.830Pre Close221.46KTurnover0.39%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.50P/B57.08MFloat Cap1.55052wk Low--Dividend TTM30.69MShs Float24.420Historical High--Div YieldTTM3.83%Amplitude1.550Historical Low1.848Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet